Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: Inverse Gaussian density absorption and 2-compartment disposition

Clinical Pharmacology and Therapeutics

Volumn 72, Issue 1, 2002, Pages 10-19

  Zhang, Xiaoping ^a,b,c,d   Nieforth, Keith ^a,b,c,d   Lang, Jean Marie ^a,b,c,d   Rouzier Panis, Regine ^a,b,c,d   Reynes, Jacques ^a,b,c,d   Dorr, Albert ^a,b,c,d   Kolis, Stanley ^a,b,c,d   Stiles, Mark R ^a,b,c,d   Kinchelow, Tosca ^a,b,c,d   Patel, Indravadan H ^a,b,c,d  

^a HOFFMANN LA ROCHE INC   (United States)

^b HÔPITAL CIVIL   (France)

^c Center CAP Clinique Rech   (France)

^d MDS Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ENFUVIRTIDE;

ADULT; ARTICLE; BIOAVAILABILITY; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIQUID CHROMATOGRAPHY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TANDEM MASS SPECTROMETRY;

ABSORPTION; ADULT; ALGORITHMS; ANTI-HIV AGENTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NORMAL DISTRIBUTION; PEPTIDE FRAGMENTS;

EID: 0036335809     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2002.125945     Document Type: Article

References (23)

1. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120
2. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor
3. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry
4. Forty-eight week analysis of patients receiving T-20 as a component of multi-drug salvage therapy
5. Safety, pharmacokinetics, and antiviral activity of T-20 as a single agent in heavily pre-treated patients
6. Patient satisfaction and activities of daily living (ADL) in HIV-infected adults using T-20 given by subcutaneous injection (SC) over 48 weeks
7. A week 48 assessment of a randomized, open-label phase II trial (T20-206) evaluating 3 doses of T-20 in PI-experienced, NNRTI-naive patients infected with HIV-1
8. LC/MS/MS assay validation of T-20 in human EDTA plasma
9. A novel extravascular input function for the assessment of drug absorption in bioavailability studies
10. Use of gamma distributed residence times in pharmacokinetics
11. The simulation algorithms
12. Modeling absorption kinetics of subcutaneous injected soluble insulin
13. Models of subcutaneous insulin kinetics: A critical review
14. The pharmacokinetics of insulin after continuous subcutaneous infusion or bolus subcutaneous injection in diabetic patients
15. Insulin responses to varying profiles of subcutaneous insulin infusion: Kinetic modeling studies
16. A model for multiple subcutaneous insulin injections developed from individual diabetic patient data
17. Closed-loop subcutaneous insulin infusion algorithm with a short-acting insulin analog for long-term clinical application of a wearable artificial endocrine pancreas
18. Computer simulation of plasma insulin and glucose dynamics after subcutaneous insulin injection
19. Pharmacokinetic model for the absorption of subcutaneously injected soluble insulin and monomeric insulin analogues
20. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration